A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.

doi:10.1158/1078-0432.CCR-04-0265

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2004

Parihar Robin, Nadella Padma, Lewis Adrian, Jensen Rhonda, De Hoff Carrie, Dierksheide Julie E, VanBuskirk Anne M, Magro Cynthia M, Young Donn C, Shapiro Charles L, Carson William E

Abstract excerpt

PURPOSE: On the basis of preclinical studies, we hypothesized that interleukin (IL)12 would potentiate the antitumor actions of an antihuman epidermal growth factor receptor-2 (HER2) monoclonal antibody (trastuzumab). We conducted a Phase I trial to determine the safety and optimal biological dose of IL-12 when given in combination with trastuzumab. PATIENTS AND METHODS: Patients with metastatic HER2-positive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Chemokine CCL4

Share to Clinical Trials as Topic

Share to Interleukin-12

Share to Macrophage Inflammatory Proteins

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Open in PubMed

Identifiers

PMID: 15297404
DOI: 10.1158/1078-0432.CCR-04-0265

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.PMID 15297404Read ↗

Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.Semantic proximity Read ↗

Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancerSemantic proximity Read ↗

Gene Therapy of Cancer Based on Interleukin 12Semantic proximity Read ↗

Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model.Semantic proximity Read ↗

Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+Cytotoxic T LymphocytesSemantic proximity Read ↗

Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi anemia patient.Semantic proximity Read ↗

In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.Semantic proximity Read ↗

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.